These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 7912084)

  • 21. Predictors of disease progression in HIV-infected homosexual men with CD4+ cells < 200 x 10(6)/l but free of AIDS-defining clinical disease.
    Keet IP; Krol A; Koot M; Roos MT; de Wolf F; Miedema F; Coutinho RA
    AIDS; 1994 Nov; 8(11):1577-83. PubMed ID: 7848594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
    N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring antiretroviral activity using ICDp24 and CD4 counts in HIV infection.
    Lillo FB; Maillard M; Saracco A; Varnier OE
    J Infect; 1997 Jul; 35(1):67-71. PubMed ID: 9279727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.
    Goldstein G; Conant MA; Beall G; Grossman HA; Galpin JE; Blick G; Calabrese LH; Hirsch RL; Fisher A; Stampone P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):279-88. PubMed ID: 7859140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex.
    Pedersen C; Cooper DA; Brun-Vézinet F; Doherty R; Skinhøj P; Pérol Y; Lüthy R; Leibowitch J; Habermehl KO; Varnier OE
    AIDS; 1992 Aug; 6(8):821-5. PubMed ID: 1418778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma viremia titration and RNA quantitation in ICD-p24 negative HIV type-1-infected patients.
    Ercoli L; Sarmati L; el-Sawaf G; Cochi S; Lanti T; Iudicone P; Guglielmetti M; Giannini G; Galluzzo C; Tomino C
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1203-7. PubMed ID: 8573376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
    Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
    Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
    Crocchiolo PR; Lizioli A; Arcidiacono I; Cantaluppi P; Filippi C; Sobatti D; Bedarida G; D'Agostino F; Cambie G; Nardella ML
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1.
    Scadden DT; Pickus O; Hammer SM; Stretcher B; Bresnahan J; Gere J; McGrath J; Agosti JM
    AIDS Res Hum Retroviruses; 1996 Aug; 12(12):1151-9. PubMed ID: 8844019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated serum calprotectin levels in HIV-infected patients: the calprotectin response during ZDV treatment is associated with clinical events.
    Müller F; Frøland SS; Aukrust P; Fagerhol MK
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):931-9. PubMed ID: 7914232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.
    Levacher M; Tallet S; Dazza MC; Dournon E; Rouveix B; Pocidalo JJ
    Clin Exp Immunol; 1990 Aug; 81(2):177-82. PubMed ID: 1696859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of CD4+ T cells, HIV disease stage and zidovudine on HIV isolation in Bahia, Brazil.
    Brites C; Pedroso C; Silva N; Johnson WD; Badaró R
    Rev Soc Bras Med Trop; 1996; 29(1):5-9. PubMed ID: 8851208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine.
    Jacobson MA; De Gruttola V; Reddy M; Arduino JM; Strickland S; Reichman RC; Bartlett JA; Phair JP; Hirsch MS; Collier AC
    AIDS; 1995 Jul; 9(7):727-34. PubMed ID: 7546418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.
    Saag MS; Crain MJ; Decker WD; Campbell-Hill S; Robinson S; Brown WE; Leuther M; Whitley RJ; Hahn BH; Shaw GM
    J Infect Dis; 1991 Jul; 164(1):72-80. PubMed ID: 1676046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection.
    Dyer WB; Zaunders JJ; Yuan FF; Wang B; Learmont JC; Geczy AF; Saksena NK; McPhee DA; Gorry PR; Sullivan JS
    Retrovirology; 2008 Dec; 5():112. PubMed ID: 19077215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The prognostic markers of HIV infection progression. A study of the p24 antigen in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T
    An Med Interna; 1999 Sep; 16(9):447-50. PubMed ID: 10609356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
    Rezza G; Galai N; Pezzotti P; Vlahov D; Graham NM; Viale P; Angarano G
    Antivir Ther; 1997 Jul; 2(3):167-74. PubMed ID: 11322271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
    N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.